Trial Profile
Efficacy and Safety of Liraglutide-bolus (Liraglutide Plus Prandial Insulin) Versus Glargine-bolus Therapy in Overweight / Obese Patients With Uncontrolled Type 2 Diabetes (LiraGooD)--A Multicenter Randomized Controlled Study
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 04 Aug 2022
Price :
$35
*
At a glance
- Drugs Liraglutide (Primary) ; Insulin glargine; Insulin lispro
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms LiraGooD
- 04 Aug 2020 Planned End Date changed from 31 Dec 2020 to 31 Dec 2021.
- 04 Aug 2020 Planned primary completion date changed from 1 Dec 2020 to 1 Dec 2021.
- 19 Nov 2018 Planned number of patients changed from 304 to 140.